Skip to main content

Table 4 Observed cardio-kidney or treatment failure-related outcomes among patients with DKD initiating SGLT2i

From: Predictors of cardio-kidney complications and treatment failure in patients with chronic kidney disease and type 2 diabetes treated with SGLT2 inhibitors

 

SGLT2i initiators with DKD (N = 6389)

Commercial insurance (N = 2284)

Medicare insurance (N = 4105)

Low CV risk (N = 2797)

Moderate CV risk (N = 3237)

High CV risk (N = 355)

CV hospitalization

 

Mean (SD) follow-up time in days

292.3 (328.5)

336.3 (368.0)

267.8 (301.5)

333.0 (376.0)

266.4 (284.8)

207.0 (249.7)

Rate per 1000 PY (95% CI)

26.0 (21.6, 30.4)

16.2 (10.7, 21.6)

32.9 (26.4, 39.4)

16.5 (11.5, 21.4)

31.7 (24.6, 38.9)

79.5 (40.5, 118.4)

Kidney hospitalization

 

Mean (SD) follow-up time in days

294.6 (329.8)

339.1 (369.4)

269.9 (302.9)

 

Rate per 1000 PY (95% CI)

12.0 (9.0, 15.0)

5.7 (2.5, 8.9)

16.5 (11.9, 21.0)

AKI hospitalization

 

Mean (SD) follow-up time in days

293.5 (330.0)

338.9 (370.6)

268.3 (302.2)

Rate per 1000 PY (95% CI)

22.8 (18.7, 26.9)

12.3 (7.6, 17.0)

30.2 (24.0, 36.4)

Discontinuation of SGLT2is

 

Discontinuation, n (%)

3512 (55.0%)

1024 (44.8%)

2488 (60.6%)

Mean (SD) time to discontinuation in days

300.6 (243.9)

331.4 (282.5)

287.9 (225.0)

Median [IQR] time to discontinuation in days

204 [144, 364]

221 [143, 420]

195 [145, 348]

Treatment failure

 

Mean (SD) follow-up time in days

361.49 (365.96)

347.14 (371.94)

369.47 (362.39)

Rate per 1000 PY (95% CI)

510.46 (492.86, 528.07)

514.21 (484.06, 544.37)

508.51 (486.82, 530.19)

Reason for treatment failure

  

SGLT2i discontinuation or switch from SGLT2i to another antidiabetic drug class, n (%)

3053 (63.6%)

Addition of another antidiabetic class not used in baseline, n (%)

1495 (31.1%)

Initiation of insulin, n (%)

213 (4.4%)

Two or more reasons for treatment failure, n (%)

41 (0.9%)

  1. Abbreviations: AKI acute kidney injury, DKD diabetic kidney disease, CI confidence interval, CV cardiovascular, PY person-years, SD standard deviation, SGLT2i sodium-glucose co-transporter-2 inhibitor, T2D type 2 diabetes